13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • AMG 510 NSCLC

    Acronym: 

    AMG 510 NSCLC

    ACTRN/NCT /ethics: 

    Scientific title: 

    A Phase 3 Multicenter, Randomized, Open Label, active-controlled, Study of AMG 510 Versus Docetaxel for the Treatment of previously treated Locally Advanced and unresectable or Metastatic NSCLC Subjects with KRAS p.G12C Mutation

    Summary of trial and patient characteristics

    Cancer Type Lung & mesothelioma
    Trial Type Treatment
    Phase Phase III Tumour Stream NSCLC
    Age Range 18 years and older Cancer Stage Locally Recurrent or Locally Advanced, Metastatic or Widespread
    Sex Both Anticipated Start Date
    Molecular Target Anticipated End Date
    Cancer Type Lung & mesothelioma
    Trial Type Treatment
    Phase Phase III
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream NSCLC
    Cancer Stage Locally Recurrent or Locally Advanced, Metastatic or Widespread
    Anticipated Start Date
    Anticipated End Date

    Trial Summary

    A Phase 3 Multicenter, Randomized, Open Label, active-controlled, Study of AMG 510 Versus Docetaxel for the Treatment of previously treated Locally Advanced and unresectable or Metastatic NSCLC Subjects with KRAS p.G12C Mutation

    Lay Summary

    A Phase 3 Multicenter, Randomized, Open Label, active-controlled, Study of AMG 510 Versus Docetaxel for the Treatment of previously treated Locally Advanced and unresectable or Metastatic NSCLC Subjects with KRAS p.G12C Mutation

    Sponsor / Cooperative group

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    The Queen Elizabeth Hospital Pamela Cooper pamela.cooper@sa.gov.au 08 8222 6410 Dr Rachel Roberts-Thomson Not Yet Recruiting